Laboratory systems  

ETH Zurich adopts VisEn's fluorescence molecular tomography system for molecular imaging

30 August 2006

Woburn, Mass., USA. Eidgenössische Technische Hochschule Zürich (ETHZ — The Swiss Federal Institute of Technology Zurich) has adopted VisEn's portfolio of in vivo fluorescence probes and fluorescence molecular tomography (FMT) imaging system, for its molecular imaging programs.

VisEn's fluorescence imaging technologies and products are designed to provide robust and accurate imaging performance in identifying, characterizing and quantifying a range of biological phenomena in vivo, including known molecular activities underlying disease states such as cancer, inflammation, cardiovascular disease and bone disease.

By imaging these disease-related biologic activities in vivo, VisEn's technology platforms enable expanded areas of research and more efficient drug development. They are also designed for expansion into biologic imaging in the emerging field of personalized medicine.

VisEn Medical also announced that Dr. Markus Rudin, Professor of Molecular Imaging and Functional Pharmacology at ETHZ has joined its Scientific Advisory Board.

Kirtland G. Poss, President and Chief Executive Officer of VisEn said, "Dr. Rudin's deep scientific heritage and guiding role in molecular imaging has been one of the pioneering forces of the whole field, first in drug development with Novartis, and now in industry-leading research with ETH. Our work with Dr. Rudin over the years has been an important factor in shaping our technology platforms to date, and his further role as an advisor to VisEn will help drive our technologies and the field of molecular imaging forward. We are honoured by his participation with VisEn and see this as yet another key foundation for our company's leadership."

Dr. Rudin added, "Real-time imaging of biologic and molecular processes in vivo is playing an increasingly central role in basic research and drug development today. VisEn's FMT imaging system and probe platforms were developed in close collaboration with leading researchers, pharmaceutical companies and clinicians. The result is an unprecedented level of biologically-relevant data specificity and quantification, that together, will propel this area from basic research and pre-clinical imaging studies today and pave the way to the future of personalized medicine. I look forward to collaborating even more deeply with VisEn's Scientific Advisory Board and management on the future of this promising area of research."

To top

To top